Antigenicity and immunogenicity of a novel Plasmodium vivax circumsporozoite derived synthetic vaccine construct
JournalArticle (Originalarbeit in einer wissenschaftlichen Zeitschrift)
ID 2663216
Author(s) Céspedes, Nora; Jiménez, Eliécer; Lopez-Perez, Mary; Rubiano, Kelly; Felger, Ingrid; Alonso, Pedro; Arévalo-Herrera, Myriam; Corradin, Giampietro; Herrera, Sócrates
Author(s) at UniBasel Felger, Ingrid
Year 2014
Title Antigenicity and immunogenicity of a novel Plasmodium vivax circumsporozoite derived synthetic vaccine construct
Journal Vaccine : the official journal of the International Society for Vaccines
Volume 32
Number 26
Pages / Article-Number 3179-86
Keywords Malaria, Plasmodium vivax, Vaccine, CS protein, Long synthetic peptide, Mice
Abstract The circumsporozoite (CS) protein is a major malaria sporozoite surface antigen currently being considered as vaccine candidate. Plasmodium vivax CS (PvCS) protein comprises a dimorphic central repeat fragment flanked by conserved regions that contain functional domains involved in parasite invasion of host cells. The protein amino (N-terminal) flank has a cleavage region (region I), essential for proteolytic processing prior to parasite invasion of liver cells.; We have developed a 131-mer long synthetic polypeptide (LSP) named PvNR1R2 that includes the N-terminal flank and the two natural repeat variant regions known as VK210 and VK247. We studied the natural immune response to this region in human sera from different malaria-endemic areas and its immunogenicity in mice.; PvNR1R2 was more frequently recognized by sera from Papua New Guinea (PNG) (83%) than by samples from Colombia (24%) when tested by ELISA. The polypeptide formulated in Montanide ISA51 adjuvant elicited strong antibody responses in both C3H and CB6F1 mice strains. Antibodies from immunized mice as well as affinity-purified human IgG reacted with native protein by IFA test. Moreover, mouse immune sera induced strong (90%) in vitro inhibition of sporozoite invasion (ISI) of hepatoma cell lines.; These results encourage further studies in non-human primates to confirm the elicitation of sporozoite invasion blocking antibodies, to assess cell mediated immune responses and the protective efficacy of this polypeptide.
Publisher Elsevier ; [Online:] Amsterdam
ISSN/ISBN 0264-410X
Full Text on edoc No
Digital Object Identifier DOI 10.1016/j.vaccine.2014.04.007
PubMed ID
ISI-Number WOS:000336872500011
Document type (ISI) Journal Article

MCSS v5.8 PRO. 0.462 sec, queries - 0.000 sec ©Universität Basel  |  Impressum   |